I got into this company early this year. I love the pathways they are targeting, but they have little data or success yet to show they have great science yet.
1/ Their management is still new to me as they haven't had much data yet. Their first program was for SHP2 which had lack luster data. At least they were wise enough to partner that away for some cash. They are highly focused on the internal cell growth pathways.
2/ These are the MAPK and mTOR pathways. These are some of the hottest pathways in all oncology. The problem is the closer to the receptor you go for the pathways, the broader the suppression and the higher the toxicity.
3/ Just like with PI3K which is at the top of the mTOR pathway, SHP2 was just as toxic sitting at the top of the MAPK pathway. The big money for $RVMD will be around its many programs focused on RAS and KRAS. They have a multi RAS, KRAS G12C, KRAS G13C and KRAS G12D programs.
4/ These are competing programs and should be treated as shots on goal. If multi RAS works, it could be huge and soak up most of the KRAS programs. If it fails, they still have the specific KRAS programs to fall back on.
5/ This is a very big space with $3 to $5 billion in total potential, but they have no data yet. They are planning a big preclinical data read out for multi RAS at AACR next weekend. That could be a big mover for the stock.
6/ I have to admit. I am a bit cautious of a multi RAS target. They also have several other early stage programs around SOS1 which is near the top of the MAPK pathway and 4EBP1 which is at the end of the mTOR pathway.
7/ $RVMD has no real success yet, but they are in all the right places where success could make them the next $MRTX with a single strong data readout. Its going to come down to the data.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
My last pathway company to profile for today. They are unique as they are focused on the DNA damage repair pathways. This is a new frontier of discovery. There are not a lot of companies in this space yet.
1/ They are my first and only pure Synthetic Lethality play. Their first drug is around the ATM/ATR pathway that regulates double stranded breaks. This concept looks for pathways that cancer depends on to drive growth. It targets them to kill the cancer cells.
2/ The ATM/ATR pathway has been attempted before. It has concerns with toxicity. There is a level of concern and caution about trying new things in this same area that failed before.
It took me a long time to warm up to $SDGR. For a long time, I just dismissed it as a tech company. I could care less about a tech company. Then I found out they were developing their own pipeline.
1/ Then again, I dismissed them as a tech company pretending to be a biotech. What would a tech company know about developing drugs? I listened to a few of their presentations from their science guru. That is when I thought they had potential.
2/ They have a lot of partnerships for companies using their software developing drugs. I am not going to cover any of those as they all have different terms and levels of profit sharing. They do offer potential should they work out.
I got into this company about 6 months ago. They are an early stage company with no data yet. They have a big risk/reward profile with using AI to attempt to take on some of the most toxic targets in pathways.
1/ I spoke before about how the SPH2 and PI3K kinases are at the top of the MAPK and mTOR pathways. Being at the top of the pathway gives them strong suppression effects, but a lot of toxicity. $RLAY is taking on these targets using its AI platform to develop inhibitors.
2/ Their fist program is around SHP2 which they already partnered out. This helps mitigate any failure if the technology doesn't help improve this target more then other companies. We have no data yet on this program. This has been turned over to the partner so data is waiting.
This is a new IPO, but I jumped on it because of its management. This management was from the old Ignyta which was very successful for me in the past. I go into Ignyta early and held it until the day it was bought out. I know this is a winning management team.
1/ They remind me very much like $RVMD with a big focus on the MAPK pathway. They have no data yet, but they did dose their first patient. I would expect some early data in the Spring of next year.
2/ Their first targets are all about MAPK and using combinations of target to lock down this pathway in cancer. Many drugs will suppress the pathway, but it rebounds over time.
I got interested in $MRTX about 3 years ago while I was an Array Bio investor. They licensed some of the KRAS technology from Array. That got me interested.
1/ $MRTX just replaced their CEO. Chuck moved up to Chairman and they hired David Meek to groom into the new CEO role. He has a history with commercial experience. That is good for taking the company to the next level with approval and sales.
2/ Their original drug is Sitravatinib which hits multiple kinases. This is designed to alter the tumor microenvironment to shift things back toward cellular killing. It had some decent data for patients who developed resistance to PD-1 inhibitors.
I have been in this company just over a year now. I am pretty sure the management is strong, but it hasn't had the chance to navigate the entire process yet. They still need to show they can get a drug approved and execute on selling it.
1/ This company is working on the growth receptors pathways. They are a 2nd generation of kinase company. They are developing much smaller inhibitors that can get in there and still inhibit the kinase even with mutation. That is their big tech development.
2/ Their drugs are designed to get around and overcome resistance. Will they develop resistances of their own? My money would be on yes as cancer always mutates to find a way around most drugs.